Sequential continuous infusion with doxorubicin and vinblastine: An effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone

Forty-two patients with metastatic breast carcinoma previously treated with a combination of cyclophosphamide, methotrexate, and 5-FU, with or without vincristine or prednisone, were treated at relapse with a sequential combination of doxorubicin and vinblastine given by continuous infusion. Two patients achieved complete remission and 16 achieved partial remission for a total response rate of 43%. The median time to progression for responders and patients with stable disease was 10 and 4 months, respectively. Neutropenia was the major toxic effect but did not lead to any fatality.